🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05662540
Recruiting Not applicable

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

NCT05662540 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Not applicable
Started
2023-05-26
Last updated
2024-10-26

Condition(s) studied

NK/T-cell Lymphoma

Investigational drug(s) / intervention(s)

Positron Emission Tomography/Magnetic Resonance (PET/MR)

Positron Emission Tomography/Magnetic Resonance (PET/MR): 18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.

Study summary

This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.

Eligibility

Sex
ALL
Min age
14 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016 * Age from 14 to 70 years-old * ECOG 0-2 score * Patients with a life expectancy of at least 6 months * Patient has not been treated before for NK/T cell lymphoma * Commit to abide by the research procedures and cooperate with the implementation of the whole process of research * Written informed consent Exclusion Criteria: \- Subjects who meet any of the following criteria are not eligible for study entry * Diagnosed aggressive NK cell leukemia * Pregnant or lactating women * Liver and kidney insufficiency * Other PET/MR contraindications: 1. Those with implanted functional electronic devices such as cardiac pacemakers 2. Carotid aneurysm clipping and other implants are ferromagnetic materials 3. Implanted perfusion devices such as insulin perfusion pumps 4. Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients 5. Those who are claustrophobic * Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital Shanghai Shanghai Municipality Recruiting

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05662540 on ClinicalTrials.gov ↗ ← All trials in China